IceCure’s Nine-Month Revenue Rises 26% to $2.64 Million
IceCure Medical reported on November 18 that revenue for the first nine months of 2026 reached $2.642 million, up about 26% from $2.100 million a year earlier. The Caesarea-based medical-device company, which develops liquid-nitrogen equipment to freeze tumors, also reported a wider net loss as research and commercial spending increased. Chief executive Eyal Shamir said U.S. sales rose 83% year over year. The company’s U.S. commercial presence covered 21 states in the third quarter of 2026, compared with 11 in the same quarter of 2025. Shamir said, “At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study.” Gross profit for the nine-month period increased to $762,000 from $626,000. The financial tables put the net loss at $12.995 million, compared with $10.811 million a year earlier. Research and development expenses rose to $6.557 million from $5.137 million, mainly because of the ChoICE study and other clinical and development work. Sales and marketing expenses increased to about $3.6 million from $3.0 million as U.S. commercial operations expanded. At September 30, IceCure held approximately $8.2 million in cash and cash equivalents and reported shareholders’ equity of about $8.7 million. ChoICE is a post-marketing study of the company’s ProSense cryoablation system for local treatment of low-risk breast cancer. Initial study sites include West Cancer Center & Research Institute in Germantown, Tennessee, and Adventist Health Glendale in California. In its account of developments after the quarter ended, IceCure said the first two patients had enrolled at those sites and the first study treatment had taken place at West Cancer Center.

Commentary